A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2)

BACKGROUND: Nivolumab, an anti-programmed death-1 agent, showed survival benefits in Asian patients, including Japanese, with gastric/gastro-esophageal junction (G/GEJ) cancer. We report the analysis of the Japanese subpopulation from ATTRACTION-2 that evaluated nivolumab versus placebo in unresecta...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Ken, Satoh, Taroh, Muro, Kei, Yoshikawa, Takaki, Tamura, Takao, Hamamoto, Yasuo, Chin, Keisho, Minashi, Keiko, Tsuda, Masahiro, Yamaguchi, Kensei, Machida, Nozomu, Esaki, Taito, Goto, Masahiro, Komatsu, Yoshito, Nakajima, Takako Eguchi, Sugimoto, Naotoshi, Yoshida, Kazuhiro, Oki, Eiji, Nishina, Tomohiro, Tsuji, Akihito, Fujii, Hirofumi, Kunieda, Kenji, Saitoh, Soh, Omuro, Yasushi, Azuma, Mizutomo, Iwamoto, Yasuo, Taku, Keisei, Fushida, Sachio, Chen, Li-Tzong, Kang, Yoon-Koo, Boku, Narikazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394726/
https://www.ncbi.nlm.nih.gov/pubmed/30506519
http://dx.doi.org/10.1007/s10120-018-0899-6

Ejemplares similares

Ejemplares similares